In addition, SUMOylation by UBA2 is also operative in glioma: UBA2 and its target RALY are increased in glioma cells and UBA2 knockdown inhibits vasculogenic mimicry and glioma cell proliferation [43]. The gene discussed is UBA2; the disease is central nervous system cancer.